Results 201 to 210 of about 134,252 (360)

Randomised trials of 6 % tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. [PDF]

, 2013
A Dubin, A Godier, A Perner, AA Schramko, AG Sawyer, AJ Onwuegbuzie, Amit Patel, B Guidet, C Ertmer, C Sirtl, CJ Wiedermann, CJ Wiedermann, CL Sprung, Committee TCvHSTCM, CS Hartog, CS Hartog, CS Hartog, CS Hartog, D Moher, D Palumbo, DJ Cook, DJ Gattas, F Li, F Schortgen, FM Brunkhorst, FS Investigators, GC Zhu, H Sahai, I Roten von, J Cohen, J Lv, JA Freiman, JA Myburgh, JA Russell, JL Vincent, JL Vincent, JP Higgins, JP Higgins, JP Higgins, K Reinhart, K Reinhart, M Dolecek, M Jacob, M Schmidt-Hieber, M Sossdorf, P Matsota, R Bellmann, R Bellomo, R DerSimonian, RP Dellinger, S Finfer, S Stander, SA Kozek-Langenecker, SH Sahin, SL Shafer, SM Kasper, Stephen J. Brett, T Niemi, TA Neff, Umeer Waheed, VG Nielsen, VM Ranieri, WA Knaus   +62 more
core   +1 more source

Management of Generalized Pruritus in Dominant Dystrophic Epidermolysis Bullosa Using Low-dose Oral Cyclosporin

, 2002
Emel Çalıkoğlu, Ranâ Anadolu
openalex   +1 more source

Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus [PDF]

, 2016
Jungsoo Lee, Jung U Shin, Seongmin Noh, Chang Ook Park, Kwang Hoon Lee   +4 more
openalex   +1 more source

Cholestatic pruritus: a knowledge update

, 2022
Thaís Reginatto Nietsche, Gabriel Dotta, Carlos Baptista Barcauí, Maria Lúcia Gomes Ferraz   +3 more
openalex   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source

Mechanisms Regulating Epidermal Innervation in Pruritus of Atopic Dermatitis

, 2011
Mitsutoshi Tominaga, Kenji Takamori
openalex   +2 more sources

Culturally Safe and Decentralised Care: Patient Experiences of a Dermatology Clinic Embedded in an Aboriginal and Torres Strait Islander Primary Health Care Service

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background Skin disease is a major cause of morbidity in Australia and a leading reason for primary care visits. Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of skin conditions but face barriers to accessing culturally safe specialist services.
Nikhil Dwivedi, Nicholas Van Rooij, Geoffrey Spurling, Claudette (Sissy) Tyson, Sonya Egert, Erin McMeniman, Noel Hayman   +6 more
wiley   +1 more source

Fractional CO₂ Laser Combined With Topical Corticosteroids for Vulvar Lichen Simplex Chronicus: An Observational Study From an 8-Year Single-Center Experience. [PDF]

Lasers Surg Med
Wei D, Meng J, Zhu Y, Li Q, Wang Y, Chen Y, Niu X.   +6 more
europepmc   +1 more source

Points from Letters: Antihistamine Drug for Pruritus of Jaundice

, 1947
Df. Wilson
openalex   +2 more sources

Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial

Allergy, EarlyView.
The RHAPSODY multinational study investigated 26 months of continuous treatment with 5‐grass‐pollen sublingual SLIT drops in adults with moderate‐to‐severe grass‐pollen‐induced allergic rhinoconjunctivitis. The primary efficacy endpoint (the average daily total combined score) showed statistically significant differences in favour of the active ...
Alain Didier, Ruta Gronskyte Juhl, Terrie Dalgaard, Antoine Chartier, Philippe Devillier   +4 more
wiley   +1 more source